Please login to the form below

Not currently logged in
Email:
Password:

VBP

This page shows the latest VBP news and features for those working in and with pharma, biotech and healthcare.

Novo Nordisk growth takes a hit with China deal

Novo Nordisk growth takes a hit with China deal

The value-based procurement (VBP) process in China will cover all insulins supplied in hospitals and is expected to be implemented in the first half of 2022.

Latest news

  • Cancer Drugs Fund overhaul promises faster access to drugs Cancer Drugs Fund overhaul promises faster access to drugs

    always meant to be a stop-gap measure while the UK developed a value-based pricing (VBP) scheme for medicines. ... The failure of the VBP initiative has meant that the CDF has extended much longer than originally anticipated and it has careened over

  • NHS England proposes handing CDF remit to NICE NHS England proposes handing CDF remit to NICE

    VBP however failed to be approved and the issues around access from 2010 remain today; politically it has also proved difficult for the government to remove this Fund as it has

  • GSK found UK's drug pricing changes a tough sell GSK found UK's drug pricing changes a tough sell

    At that point in the negotiations the government was still looking to heavily rely on a brand new value-based pricing (VBP) approach to assessing new medicine costs – a method that ... Several months after Sir Andrew's meeting a new PPRS plan was

  • England's Cancer Drugs Fund: Fixing a broken system England's Cancer Drugs Fund: Fixing a broken system

    as value-based pricing (VBP), would overcome the market access problems that saw NICE reject so many of these drugs. ... VBP died a long, slow death in 2013 however and was replaced with a similar system to that used for over 50 years in the UK, meaning

  • Cancer Drugs Fund is not NICE replacement Cancer Drugs Fund is not NICE replacement

    The Fund was initially meant to last for three years until the introduction of value-based pricing (VBP) in the UK.

More from news
Approximately 7 fully matching, plus 26 partially matching documents found.

Latest Intelligence

  • The death of the cancer drugs fund? The death of the cancer drugs fund?

    of a new drug pricing system, known as value-based pricing (VBP). ... VBP however failed to be approved and the issues around access from 2010 remain today; politically it has also proved difficult for the government to remove this Fund as it has

  • UK market access: The importance of a local value story UK market access: The importance of a local value story

    Finally, there is the spectre of a new drug pricing policy in the guise of value-based pricing (VBP) that is due to come into effect at the start of 2014. ... With VBP, though still an unknown quantity for pharma and, perhaps just as worryingly, the

  • Interview: David Haslam, NICE Interview: David Haslam, NICE

    The new chair of the UK’s NICE discusses navigating the stormy waters of health service reforms, collaborating with pharma and the introduction of VBP. ... Little is known about what this will entail, however, although it has been confirmed that NICE

  • Interview: Cesar Rodriguez, Janssen Interview: Cesar Rodriguez, Janssen

    We are concerned about the implications of the value-based pricing (VBP) system of reimbursement that the government wants to implement from 2014, because as an investor, one of the things

  • The true meaning of market access? The true meaning of market access?

    For example, the UK plans to introduce Value-based Pricing (VBP) for NCEs in 2014, based on a range of cost-effectiveness thresholds, which in turn are based on disease burden, ... We need'parametric' VBP, variable over time. However, there is little

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
TRIDUCIVE

Triducive are a strategic healthcare consultancy who produce communications that have practical, dynamic application that encourage behaviour change because of the...

Latest intelligence

Diversity in clinical trials: looking back at our 2021 blogs
In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:
Securing a future for telehealth with immersive market research insights...